References
- Illingworth R N. Glucagon for beta-blocker poisoning. Practitioner 1979; 223: 863–865
- Kosinski E J, Malindzak G S, Jr. Glucagon and isoproterenol in reversing propranolol toxicity. Arch Intern Med 1973; 132: 840–843
- Robson R H. Glucagon for beta-blocker poisoning. Lancet 1980; 1: 1357–1358
- Ward D E, Jones B. Glucagon and beta-blocker toxicity. Br Med J 1976; 2: 151
- Parmley W W. The role of glucagon in cardiac therapy. N Engl J Med 1971; 285: 801–802
- Love J N, Leasure J A, Mundt D J, Janz T G. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Toxicol Clin Toxicol 1992; 30: 399–412
- Anderson J L, Baim D S, Fein S A, Goldstein R A, LeJemtel T H, Likoff M J. Efficacy and safety of sustained (48 h) intravenous infusions of milrinone in patients with severe congestive heart failure; a multicenter study. J Am Coll Cardiol 1987; 9: 711–722
- Baim D S, McDowel A V, Chernilles J, et al. Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N Engl J Med 1983; 309: 748–756
- Maskin C S, Sinoway L, Chadwick B, Sonnenblick E H, LeJemtel T H. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation 1983; 67: 1065–1070
- Critchley J A, Ungar A. The management of acute poisoning due to beta-adrenoceptor antagonists. Med Toxicol 1989; 4: 32–45
- Weinstein R S. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med 1984; 13: 1123–1131
- Tynan R F, Fisher M M, Ibels L S. Self-poisoning with propranolol. Med J Aust 1981; 21: 82–83
- Shore E T, Cepin D, Davidson M J. Metoprolol overdose. Ann Emerg Med 1981; 10: 524–527
- Glick G, Parmley W W, Wechsler A S, Sonnenblick E H. Glucagon — its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol. Cir Res 1968; 22: 789–799
- Lucchesi B R. Cardiac actions of glucagon. Cir Res 1968; 22: 777–787
- Jacobsen D, Helgeland A, Koss A. Treatment of beta-blocker poisoning. Lancet 1980; 1: 1031–1032
- Endoh M, Yamashita S, Taira N. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharmacol Exp Ther 1982; 221: 775–783
- Kariya T, Wille L J, Dage R C. Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043. J Cardiovasc Pharmacol 1982; 4: 509–514
- Hayes J S, Bowling N, Boder G B, Kauffman R. Molecular basis for the cardiovascular activities of amrinone and AR-L57. J Pharmacol Exp Ther 1984; 230: 124–132
- Bristol J A, Sircar I, Moos W H, Evans D B, Weishaar R E. Cardiotonic agents. J Med Chem 1984; 27: 1099–1101
- Alousi A A, Farah A E, Lesher G Y, Opalka C J, Jr. Cardiotonic activity of amrinone-Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one]. Cir Res 1979; 45: 666–677
- Alousi A A, Canter J M, Montenaro M J, Fort D J, Ferrari R A. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983; 5: 792–803
- Jaski B E, Fifer M A, Wright R F, Braunwald E, Colucci W S. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J Clin Invest 1985; 75: 643–649
- Monrad E S, McKay R G, Baim D S, et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 1984; 70: 1030–1037
- Monrad E S, Baim D S, Smith H S, Lanoue A S. Milrinone, dobutamine and nitroprusside:comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 1986; 73(Suppl): 168–174